← All Biolife Solutions INC filings

Biolife Solutions INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
BLFS
Biolife Solutions INC
DEFA14A: BioLife Solutions Files Definitive Proxy Statement with SEC
BioLife Solutions, Inc. has filed its definitive proxy statement, Schedule 14A, with the U.S. Securities and Exchange Commission.
NASDAQ
BLFS
Biolife Solutions INC
DEF: BioLife Solutions Reports Strong 2024 Financials and Strategic Realignment, Outperforming Peer Group TSR
BioLife Solutions, Inc. announced robust 2024 financial results, including significant revenue growth and positive adjusted EBITDA, driven by strategic divestitures and a sharpened focus on the cell and gene therapy market, while also detailing executive compensation and corporate governance updates ahead of its 2025 Annual Meeting.
NASDAQ
BLFS
Biolife Solutions INC
DEFA14A: BioLife Solutions Addresses Material Weaknesses and Outlines 2024 Remediation Plan
BioLife Solutions is actively addressing material weaknesses identified in its FY23 SOX compliance program, focusing on system implementation, internal controls, and resource expertise.
NASDAQ
BLFS
Biolife Solutions INC
DEF 14A: BioLife Solutions Sets Date for 2024 Annual Stockholders Meeting
BioLife Solutions will hold its 2024 Annual Meeting of Stockholders virtually on August 1, 2024, to vote on director elections, executive compensation, and auditor ratification.